Changing Perspective on Oncometabolites: from Metabolic Signature of Cancer to Tumorigenic and Immunosuppressive Agents

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Apr 16

PMID 27083002

Citations 16

Authors

Mauro Corrado

Luca Scorrano

Silvia Campello

Affiliations

Soon will be listed here.

Abstract

During tumorigenesis, the shift from oxidative phosphorylation to glycolysis in ATP production accounts for the dramatic change in the cellular metabolism and represents one of the major steps leading to tumour formation. The so-called Warburg effect is currently considered something more than a mere modification in the cellular metabolism. The paradox that during cancer cell proliferation the increase in energy need is supplied by glycolysis can be only explained by taking into account the many roles that intermediates of glycolysis or TCA cycle play in cellular physiology, besides energy production. Recent studies have shown that metabolic intermediates induce changes in chromatin structure or drive neo-angiogenesis. In this review, we present some of the latest findings in the study of cancer metabolism with particular attention to how tumour metabolism and its microenvironment can favour tumour growth and aggressiveness, by hijacking and dampening the anti-tumoral immune response.

Citing Articles

FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression.

Hu C, Ye M, Bai J, Liu P, Lu F, Chen J Cell Mol Life Sci. 2024; 81(1):50.

PMID: 38252148 PMC: 10803496. DOI: 10.1007/s00018-023-05084-0.

Chromatin balances cell redox and energy homeostasis.

Suganuma T, Workman J Epigenetics Chromatin. 2023; 16(1):46.

PMID: 38017471 PMC: 10683155. DOI: 10.1186/s13072-023-00520-8.

Targeting Oncometabolites in Peritoneal Cancers: Preclinical Insights and Therapeutic Strategies.

Nadhan R, Kashyap S, Ha J, Jayaraman M, Song Y, Isidoro C Metabolites. 2023; 13(5).

PMID: 37233659 PMC: 10222714. DOI: 10.3390/metabo13050618.

Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.

Evans J, Suman S, Goruganthu M, Tchekneva E, Guan S, Arasada R J Natl Cancer Inst. 2023; 115(11):1404-1419.

PMID: 37195421 PMC: 10637048. DOI: 10.1093/jnci/djad091.

4-Pyridone-3-carboxamide-1-β-D-ribonucleoside (4PYR)-A Novel Oncometabolite Modulating Cancer-Endothelial Interactions in Breast Cancer Metastasis.

Koszalka P, Kutryb-Zajac B, Mierzejewska P, Tomczyk M, Wietrzyk J, Serafin P Int J Mol Sci. 2022; 23(10).

PMID: 35628582 PMC: 9145394. DOI: 10.3390/ijms23105774.

References

Johansson M, DeNardo D, Coussens L . Polarized immune responses differentially regulate cancer development. Immunol Rev. 2008; 222:145-54. PMC: 2494984. DOI: 10.1111/j.1600-065X.2008.00600.x. View

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M . Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007; 109(9):3812-9. DOI: 10.1182/blood-2006-07-035972. View

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

Dang C, Le A, Gao P . MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009; 15(21):6479-83. PMC: 2783410. DOI: 10.1158/1078-0432.CCR-09-0889. View

Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Beznoussenko G, Rudka T . OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell. 2006; 126(1):177-89. DOI: 10.1016/j.cell.2006.06.025. View

Lombardi L, Newcomb E, Dalla-Favera R . Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell. 1987; 49(2):161-70. DOI: 10.1016/0092-8674(87)90556-3. View

Sukumar M, Liu J, Mehta G, Patel S, Roychoudhuri R, Crompton J . Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metab. 2015; 23(1):63-76. PMC: 4747432. DOI: 10.1016/j.cmet.2015.11.002. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

10.

Lu J, Sharma L, Bai Y . Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009; 19(7):802-15. PMC: 4710094. DOI: 10.1038/cr.2009.69. View

11.

Brandon M, Baldi P, Wallace D . Mitochondrial mutations in cancer. Oncogene. 2006; 25(34):4647-62. DOI: 10.1038/sj.onc.1209607. View

12.

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

13.

Contractor T, Harris C . p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res. 2011; 72(2):560-7. DOI: 10.1158/0008-5472.CAN-11-1215. View

14.

Liu J, Zhang C, Hu W, Feng Z . Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 2013; 356(2 Pt A):197-203. PMC: 4069248. DOI: 10.1016/j.canlet.2013.12.025. View

15.

Baysal B, Ferrell R, Willett-Brozick J, Lawrence E, Myssiorek D, Bosch A . Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000; 287(5454):848-51. DOI: 10.1126/science.287.5454.848. View

16.

Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y . Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 2009; 23(6):1685-93. PMC: 2718802. DOI: 10.1096/fj.08-126458. View

17.

Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R . Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007; 110(4):1225-32. DOI: 10.1182/blood-2006-12-064527. View

18.

De Rosa V, Galgani M, Porcellini A, Colamatteo A, Santopaolo M, Zuchegna C . Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol. 2015; 16(11):1174-84. PMC: 4868085. DOI: 10.1038/ni.3269. View

19.

Ternette N, Yang M, Laroyia M, Kitagawa M, OFlaherty L, Wolhulter K . Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep. 2013; 3(3):689-700. PMC: 3617368. DOI: 10.1016/j.celrep.2013.02.013. View

20.

Deaglio S, Dwyer K, Gao W, Friedman D, Usheva A, Erat A . Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007; 204(6):1257-65. PMC: 2118603. DOI: 10.1084/jem.20062512. View